MX2023003997A - Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les). - Google Patents

Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).

Info

Publication number
MX2023003997A
MX2023003997A MX2023003997A MX2023003997A MX2023003997A MX 2023003997 A MX2023003997 A MX 2023003997A MX 2023003997 A MX2023003997 A MX 2023003997A MX 2023003997 A MX2023003997 A MX 2023003997A MX 2023003997 A MX2023003997 A MX 2023003997A
Authority
MX
Mexico
Prior art keywords
biomarkers
methods
sle
systemic lupus
compositions
Prior art date
Application number
MX2023003997A
Other languages
English (en)
Inventor
Raphael Clynes
John R Desjarlais
Ying Ding
Bartholomew Burington
Debra J Zack
Paul Foster
Joel Gutheridge
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of MX2023003997A publication Critical patent/MX2023003997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Abstract

La descripción se refiere a métodos para detectar uno o más biomarcadores, y/o tratar enfermedades autoinmunitarias tales como el lupus eritematoso sistémico (LES) con un anticuerpo anti-CD19 en base a la presencia de tales biomarcadores. Los biomarcadores pueden estar separados o combinados, y su detección puede usarse en múltiples métodos diferentes.
MX2023003997A 2020-10-06 2021-10-06 Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les). MX2023003997A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088444P 2020-10-06 2020-10-06
US202063108138P 2020-10-30 2020-10-30
PCT/US2021/053790 WO2022076573A1 (en) 2020-10-06 2021-10-06 Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)

Publications (1)

Publication Number Publication Date
MX2023003997A true MX2023003997A (es) 2023-06-15

Family

ID=78709524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003997A MX2023003997A (es) 2020-10-06 2021-10-06 Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).

Country Status (9)

Country Link
EP (1) EP4225794A1 (es)
JP (1) JP2023544200A (es)
KR (1) KR20230104152A (es)
AU (1) AU2021357805A1 (es)
CA (1) CA3194386A1 (es)
IL (1) IL301865A (es)
MX (1) MX2023003997A (es)
TW (1) TW202229349A (es)
WO (1) WO2022076573A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235852A1 (en) * 2022-06-03 2023-12-07 Zenas Biopharma, Inc. Methods and compositions for treating igg4- related diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
EP2059536B1 (en) 2006-08-14 2014-01-08 Xencor, Inc. Optimized antibodies that target cd19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.

Also Published As

Publication number Publication date
TW202229349A (zh) 2022-08-01
KR20230104152A (ko) 2023-07-07
WO2022076573A9 (en) 2022-05-19
CA3194386A1 (en) 2022-04-14
JP2023544200A (ja) 2023-10-20
IL301865A (en) 2023-06-01
AU2021357805A9 (en) 2023-07-13
AU2021357805A1 (en) 2023-05-04
EP4225794A1 (en) 2023-08-16
WO2022076573A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
BR112017025051A2 (pt) ensaio celular para detecção de homodímeros anti-cd3
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
MX2016013176A (es) Uso compartido de contenidos en base al vehiculo.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2014143977A3 (en) Biomarkers and methods for predicting preeclampsia
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
NZ706187A (en) Assays for the detection of anti-tnf drugs and autoantibodies
WO2014065889A3 (en) Multiplexed method for diagnosing classical hodgkin lymphoma
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
MX2016005834A (es) Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
GB0711327D0 (en) Diagnostic method
WO2018060739A8 (en) Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CN106574223A8 (zh) 利用俘获缀合物的免疫测定
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
MX2023003997A (es) Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
Haghbin et al. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease
MX2016007148A (es) Metodos de ensayo de beta-glucano.
EP2913675A3 (en) GP2 isoforms and their use in autoantibody capture
MX2019004207A (es) Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal.
AU2023201289B2 (en) Marker for pancreatic cancer and intraductal papillary mucinous neoplasms
MX2021003484A (es) Metodos para detectar efecto(s) hook asociado(s) con analito(s) de interes durante o que resulta(n) de la realizacion de ensayo(s) de diagnostico.